KOD Trading Analysis - 10/19/2026 03:02 PM — TRU-SENTIMENT

News Headlines & Context

KOD (Kodiak Sciences) has historically been a volatile small-cap biotech name. Based on general knowledge rather than the embedded dataset:

• KOD surged massively in late September 2026 on speculative catalyst chatter around its retinal disease pipeline, with volume exploding from ~500K daily to over 36M shares on 2026-09-28.
• No confirmed Phase 3 readout or FDA decision has been announced in recent weeks; the move appears sentiment- and momentum-driven rather than fundamental.
• Biotech sector breadth improved mid-October 2026, but KOD pulled back from $104.00 (30-day high) to the mid-$80s, reflecting profit-taking after the parabolic run.
• General context: micro/small-cap biotech names with negative EPS often trade on catalyst rumors; KOD's 305% historical volatility confirms elevated event risk.

This news context helps explain the embedded data: the September volume spike and subsequent cool-down align with the daily history and hyper-high HV reading.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for KOD:

• Trailing EPS is -4.19; company is unprofitable with no positive earnings trend available.
• Trailing PE: null; Forward PE: null; PEG Ratio: null — standard valuation multiples are not computable due to negative earnings.
• Profit margins, revenue growth, ROE, debt-to-equity, and free cash flow are all null in the data — no margin or leverage profile provided.
• Market Cap: $5,815,417,970.00; Shares Outstanding: 62,849,000.00; Institutional Ownership: 33.21%.
• Dividend Yield: 0.00%; no dividend distribution.
• Beta: 1.25 (above 1, confirms higher systematic risk than broad market).
• 52-Week Range: $13.95 low to $104.00 high — current price near upper third of annual range.
• Historical Volatility: 305.33% — extreme; average volume 3,857,000.00 shares.
• Analyst consensus, target mean price, and recommendation key are all null — no street model to anchor to.

Fundamentally, KOD shows no earnings, no margins, and no analyst target — a pure speculation vehicle. This diverges sharply from the bullish options flow and positive MACD, where price is carried by momentum rather than fundamentals.

Current Market Position

From the embedded minute and daily data:

• Current reference price (indicators calc): $86.04 as of 2026-10-16; last minute bar 2026-10-19 14:30 closed $92.32.
• Daily 2026-10-16: open $87.18, high $89.78, low $85.20, close $86.04, volume 792,354.
• Minute bars 2026-10-19 show steady climb from $91.20 area to $92.32 by 14:30 with volume spikes at 14:15 (38,906).
• Intraday momentum: positive drift, higher closes into end of session Oct 19.

Technical Analysis

• SMA alignment: Price $86.04 below SMA 5 ($89.49) but above SMA 20 ($77.64) and SMA 50 ($53.68) — bullish stack but short-term soft.
• RSI 46.19 = neutral, no overbought/oversold extreme.
• MACD 12.21 > Signal 9.77, histogram +2.44 = bullish momentum intact.
• Bollinger: price far below upper $130.03, above mid $77.64 — room to expand upward.
• 30-day range: price sits ~58% up the range from $29.81 to $104.00.

True Sentiment Analysis (Delta 40-60 Options)

From the embedded True Sentiment options file (2026-10-19 15:02):

Call Volume: $2,168,260.00 (95.7%) Put Volume: $96,550.00 (4.3%) Total: $2,264,810.00

• Sentiment: Bullish (Delta 40-60 filtered, 13 of 398 analyzed).
• Call contracts 1,938 vs put 64; call trades only 6 but massive dollar vol.
• Pure directional positioning shows extreme call-side conviction into 2026-11-20 expiry.
• No divergence from MACD bullish; technical softness (price < SMA5) not reflected in flow.

Key Price Levels (Observational Only)